Loading organizations...
§ Private Profile · Lyngby, Hovedstaden, Denmark
Biotechnology company developing binding proteins to strengthen gut health and combat antimicrobial resistance in humans and animals.
Based in Copenhagen, Denmark, Bactolife is a biotechnology company that develops proprietary binding proteins to prevent gastrointestinal infections and combat antimicrobial resistance in humans and animals. The enterprise engineers biologic solutions that neutralize harmful gut pathogens without disrupting beneficial bacteria, formulating these proteins into affordable food and feed additives for the agricultural and healthcare sectors. The startup targets a global health challenge involving over 1.6 billion annual cases of diarrheal diseases, aiming to reduce infant malnutrition in developing nations. To scale its research and development operations, Bactolife has secured more than €30 million in Series A financing led by ATHOS, alongside investments from Novo Holdings and a $5 million grant from the Bill & Melinda Gates Foundation. The organization was founded in 2017 by Mads Laustsen, Sandra Wingaard Thrane, Andreas Hougaard Laustsen-Kiel, and Per Falholt.
Bactolife has raised $73.0M across 3 funding rounds.
Bactolife has raised $73.0M in total across 3 funding rounds.
Bactolife has raised $73.0M in total across 3 funding rounds.
Bactolife's investors include Donna Parr, Sara Sande, Sophia Heyde, PhD, ATHOS, Julian Zachmann, Aleks Engel, Bill & Melinda Gates Foundation.
Bactolife has raised $73.0M across 3 funding rounds. Most recently, it raised $35.1M Series B in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 6, 2026 | $35.1M Series B | Donna Parr, Sara Sande | Sophia Heyde, PHD, Athos | Announced |
| Aug 8, 2023 | $32.9M Series A | Julian Zachmann | Aleks Engel, Bill & Melinda Gates Foundation | Announced |
| Aug 30, 2022 | $5M Venture Round | Bill & Melinda Gates Foundation | — | Announced |